A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

NCT04201080 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Because there have been significant enrollment struggles which has been exacerbated by the COVID impact. This has caused an undue delay to the study timelines and its enrollment goals beyond the business needs.

Conditions

Migraines

Interventions

DRUG: Part A: TRV250-20mg/ml
DRUG: Placebo
DRUG: Part B: TRV250 Dose 1
DRUG: Part B: TRV250 Dose 2
DRUG: Part B: TRV250 Dose 3
DRUG: Placebo

Sponsor

Trevena Inc.